For example, when Pin1 is inhibited, hepatocellular carcinoma (HCC) cells have been shown to become sensitive to sorafenib [68], breast cancer cells to trastuzumab [69] and rapamycin [70], and colon cancer cells to taxol [71]. Here, PIN1 is linked to hepatocellular carcinoma.